Current Report Filing (8-k)
June 09 2016 - 8:52AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
June
9, 2016
AGENUS
INC.
(Exact
name of registrant as specified in its charter)
DELAWARE
|
000-29089
|
06-1562417
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
3 Forbes Road
Lexington, MA
|
02421
|
(Address of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
781-674-4400
N/A
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2. below):
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other Events.
Agenus Inc. (the “Agenus”) announced today the selection of a lead
product candidate under its license and research collaboration with
Merck. Merck, known as MSD outside the United States and Canada, has
selected a lead antibody candidate and several backup antibodies,
discovered by Agenus, to an undisclosed Merck checkpoint target. Based
on this milestone and under the terms of the agreement, Agenus received
a $2 million milestone payment from Merck. As previously announced,
Merck will be responsible for all future product development expenses
for the selected antibody candidate and Agenus is eligible to receive up
to $100 million in milestone payments, as well as royalties on worldwide
product sales.
The full text of the press release issued in connection with the
announcement is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
Description of Exhibit
|
|
|
99.1
|
Press Release dated June 9, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date:
|
June 9, 2016
|
AGENUS INC.
|
|
|
|
|
|
By:
|
/s/ C. Evan Ballantyne
|
|
|
|
|
C. Evan Ballantyne
|
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX
Exhibit No.
|
Description of Exhibit
|
|
|
99.1
|
Press Release dated June 9, 2016.
|
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2023 to Aug 2024